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Abstract
The adulticidal efficacy of a topical combination 
of emodepside 2.1  % (w/v) plus praziquantel 8.6 % 
(w/v) (Profender® spot-on for cats, Bayer) against 
adult Aelurostrongylus abstrusus nematodes was 
evaluated in two randomised, placebo-controlled 
laboratory efficacy studies. Each study involved 
16 cats experimentally inoculated with L3 (800 and 
600 each in studies no. 1 and 2, respectively) and 
randomised into two study groups of 8 cats each 
after onset of patency. While cats in the treatment 
group in study no. 1 received a single spot-on appli-
cation at the minimum therapeutic dose (3 mg/kg 
emodepside and 12 mg/kg praziquantel), cats in 
study no. 2 were treated twice with an interval 
of 14 days. The faecal output of first stage larvae 
was monitored throughout the study. Necropsy was 
conducted 4 or 5 weeks after the (first) treatment 
and the worm counts were used for efficacy calcula-
tions. The control groups showed a geometric mean 
of the total worm count (live and dead worms) of 
28.8 (study no. 1) and 17.6 (study no. 2), respec-
tively. All control animals were infected. While the 
single treatment in study no. 1 resulted in a reduc-
tion of the total worm burden by 73.0 % (p = 0.0070), 
the treatment protocol in study no. 2 was 99.2 % 
effective (p = 0.0035). Based on live worm counts, 
the efficacy in study no. 2 was 100 % (p = 0.0030). 
It is concluded that two applications of Profender® 
spot-on given two weeks apart represent a safe and 
highly efficacious treatment regime against feline 
aelurostrongylosis.
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Introduction
In the past few years, increased attention has been 
paid to nematode infections of the cardiopulmonary 
system of cats and dogs due to their spread in sev-
eral geographic areas (Traversa et al. 2010). In cats, 
Aelurostrongylus (A.) abstrusus is deemed to be the 
main agent causing verminous pneumonia. Adults 
of this metastrongylid nematode inhabit the alveo-
lar ducts and lung parenchyma of domestic cats and 
wild felids. The females produce eggs that embry-
onate and hatch in the lung tissue. Aided by the 
mucociliary clearance mechanisms, the first stage 
larvae (L1) migrate up the tracheobronchial tree, 
are swallowed and are released with the cat’s faeces 
into the environment (Scott 1973). The indirect life 
cycle involves various terrestrial or aquatic slugs 
and snails as intermediate hosts (Hobmeier and 
Hobmaier 1935a, Ash 1970). After ingestion of an 
infected snail, rodents, birds, amphibians and rep-
tiles may serve as paratenic hosts (Hobmeier and 
Hobmaier 1935b). Cats become infected by ingest-
ing intermediate or paratenic hosts. Depending on 
the worm burden, age and immune response of the 
infected animal, the clinical presentation varies 
from asymptomatic to fatal. Symptoms include res-
piratory signs such as dyspnoea, coughing, sneez-
ing and nasal discharge and unspecific signs such 
as lethargy, depression and weight loss (Hamilton 
1967, Scott 1973, Schnyder et al. 2014). Aeluro-
strongylus abstrusus has a worldwide distribution 
and, although the infection is considered sporadic in 
many countries, prevalences can reach around 20 % 
in endemic areas, e.g. Portugal (Payo-Puente et al. 
2008) and Italy (Traversa et al. 2008).
Anthelmintics used in recent years against A. abstru-
sus include the benzimidazole fenbendazole and 
various macrocyclic lactones. In the United King-
dom, various formulations of fenbendazole (paste, 
suspension, granules) are licensed for the treatment 
of A. abstrusus at a dosage of 50 mg/kg daily for 
three consecutive days. While some authors confirm 
the efficacy of this treatment protocol (Schmid and 
Duewel 1990, Barrs et al. 1999), others experienced 
only partial activity against adult parasites, and 
reappearance of first stage larvae (L1) in the fae-
ces of 5 of 15 treated cats (Roberson and Burke 
1980). Grandi et al. (2005) stated that a 15-day 
treatment course at 50 mg/kg was necessary with 
a tablet formulation of fenbendazole, and treatment 
recommendations for a duration of up to 21 days 
can also be found in the literature (Norsworthy 
2011, Vig and Murray 1986). In contrast, Hamilton 
et al. (1984) successfully treated experimentally 
infected cats with only five daily doses of 20 mg/
kg of a 2.5 % suspension of fenbendazole. Among 
the macrocyclic lactones, a single administration 
of 0.4 mg/kg ivermectin s.c. was successful in one 
of two cats, while the other needed a second treat-
ment to be cleared of L1 in the faeces (Burgu and 
Sarimehmetoğlu 2004). Incomplete efficacy of a sin-
gle treatment with ivermectin has been confirmed 
by other authors (Grandi et al. 2005, Kirkpatrick 
and Megella 1987). Similarly variable results were 
obtained with a selamectin spot-on. Two treatments 
given five weeks apart were successful in one cat 
(Reinhardt et al. 2004), while the same treatment 
regimen failed in another case (Grandi et al. 2005). 
In the same report by Grandi et al. (2005), one cat 
was successfully treated with a single topical treat-
ment. In a field study, 9 of 10 cats showed a nega-
tive faecal larval count after two treatments given 
23 days apart (Iannino et al. 2013). Traversa et al. 
(2009a) evaluated the efficacy of a single applica-
tion of imidacloprid/moxidectin spot-on in a posi-
tive controlled field efficacy study. While the faeces 
of all 12 imidacloprid/moxidectin-treated cats were 
free of A. abstrusus L1 four weeks after treatment, 
one cat in the control group that had been treated 
with 50 mg/kg fenbendazole for three consecutive 
days still showed a positive faecal L1 count. The 
efficacy of eprinomectin in a topical combination of 
eprinomectin/fipronil/(S)-methoprene and praziqu-
antel has been evaluated in an experimental study. 
After a single treatment 32 days post inoculation 
(dpi), faecal larval counts were reduced by 99.6 % 
compared to a negative control group (Knaus et al. 
2014).
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Profender® spot-on for cats is a combination of 
emodepside and praziquantel. Emodepside belongs 
to the cyclooctadepsipeptide class and is effective 
against a wide variety of gastrointestinal nema-
todes in cats and dogs. In a field efficacy study 
conducted by Traversa et al. (2009b) emodepside/
praziquantel spot-on showed promising results in 
the treatment of feline aelurostrongylosis. Four 
weeks after a single application, 11 of 12 treated 
cats were negative at the faecal examination and 
symptomatic cats had clinically recovered. 
The aim of the studies presented here, was to 
evaluate the efficacy of the topical emodepside/
praziquantel solution in a controlled laboratory 
test situation.
Materials and methods
Two studies were conducted to evaluate the effi-
cacy of emodepside/praziquantel spot-on against 
experimental A. abstrusus infections in cats. Both 
studies were performed as placebo-controlled, 
randomised and blinded laboratory efficacy stud-
ies. While study no. 1 evaluated the efficacy of a 
single treatment, cats in study no. 2 were treated 
twice with an interval of two weeks. Investigations 
were conducted in accordance with VICH guide-
line 9 “Good Clinical Practice” (June 2000) and 
the recommendations given in VICH Guideline 7 
“Efficacy of anthelmintics: general requirements” 
(November 2000), VICH Guideline 20 “Efficacy 
of anthelmintics: Specific Recommendations for 
Felines” (June 2001), and the WAAVP guidelines 
for evaluating the efficacy of anthelmintics for 
dogs and cats (Jacobs et al. 1994) were followed. 
As these guidelines do not include specific informa-
tion on A. abstrusus, the study design was based 
on scientific knowledge and experience gained in 
a preliminary study (Schnyder et al. 2014). The 
study designs are summarised in Table 1.
Study animals
Sixteen purpose-bred European shorthair cats 
(8 male/8 female) were included in each study. 
They were either owned by the study facility or 
purchased from commercial breeders. On the day 
of inoculation they were less than 10 months old 
and had been vaccinated against major feline 
infectious diseases. Before study start, all cats 
were dewormed once with pyrantel at the dose 
recommended by the manufacturer. Treatment 
with drugs that could influence the study results, 
especially macrocyclic lactones, was not allowed. 
All cats were acclimatised for at least 5 days prior 
to the experimental inoculation. They were either 
housed individually in cages or pens or group-
housed within their respective study group. Indi-
vidual housing was provided at least on the day 
of treatment, the two consecutive days and for 
collection of individual faecal samples. Toys and 
scratching places were offered for environmental 
enrichment. The cats received standard commer-
cial wet and/or dry food and water was available 
ad libitum. Cats were handled with due regard for 
their well-being and the protocols were approved 
by the site-specific ethics committee.
Health observations
General health observations were conducted daily 
and the cats were physically examined at least 
before infection and before treatment(s). Only 
Table 1: Summary of study designs (dpi: days post inoculation)
Study no.
No. of cats  
(treatment / control)
Age at inoculation 
(months)
Inoculation 
dose
Study day / treatment Study day / necropsy
1
8/8
3.9 – 9.2 800 L3 0 (36 dpi) 26 – 30
2 6 – 7.7 600 L3 0 and 14 (43 and 57 spi) 33 – 36
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healthy cats were included in the study. On treat-
ment day(s) clinical assessments were performed 
before treatment and approximately 1 and 4 hours 
after treatment for the detection of adverse effects. 
Body weights were determined in conjunction with 
the physical examinations.
Experimental infections
Cats were inoculated with approximately 800 
(study no. 1) or 600 (study no. 2) infective third stage 
larvae (L3) of A. abstrusus isolated from snails 
(Biomphalaria glabrata and Helix (H.) aspersa). 
The snails had been experimentally infected with 
L1 from the faeces of an A. abstrusus-positive 
cat originating from Italy. The snail tissue was 
minced and then digested for 20 – 30 minutes at 
approximately 41 °C. The solution for digestion 
was prepared by mixing 0.4 g pepsin (800 – 2500 U/
mg protein) in 250 mL of 1 % hydrochloric acid 
(HCl) solution. The digested material was passed 
through a 180 μm sieve and centrifuged at 500 g 
for 5 minutes. The supernatant was discarded and 
the number of L3 per milliliter was determined 
in a sub-sample taken from the well-stirred lar-
vae suspension. Individual inoculation doses were 
prepared and applied intragastrically via stomach 
tube. Before inoculation, the cats were anaesthe-
tised with a combination of medetomidine and 
ketamine (with or without premedication with 
acepromacine) and metoclopramide was adminis-
tered intramuscularly to avoid vomiting or regur-
gitation. After inoculation, the cats were carefully 
observed for vomiting/regurgitation and re-inocu-
lated if loss of inoculation material was observed 
within 60 minutes post inoculation.
Faecal examination
To demonstrate the parasitological status of the 
individual cat, one faecal sample was examined by 
a combined sedimentation/flotation method and by 
the Baermann technique (Baermann 1917) during 
the acclimatization period. Faecal samples of all 
cats had to be negative for nematode eggs and lar-
vae before inoculation with A. abstrusus. Starting 
30 dpi, pooled faecal samples were examined by the 
Baermann technique for L1. As soon as a pooled 
sample was positive, individual faecal samples 
were collected every other day until randomisation. 
Post-treatment faecal examinations were contin-
ued until necropsy. Individual samples were col-
lected every other day in study no. 1 and twice per 
week in study no. 2.
Allocation and treatment
After onset of patency, cats were randomly allo-
cated to two study groups based on sex and their 
highest faecal L1 count. After randomisation each 
group in the two studies consisted of 8 cats with 
equal sex distribution. Treatment was performed 
on study day (SD) 0, which was 4 to 5 days after 
all cats had shown a positive faecal larval count. 
In study no. 1 this date corresponded to 36 dpi and 
in study no. 2 to 43 dpi. In both studies, cats in 
the treatment group were dosed with the recom-
mended minimum therapeutic dose of emodepside 
(3 mg/kg) and praziquantel (12 mg/kg), correspond-
ing to 0.14 mL spot-on formulation per kilogram 
body weight. Cats in the control group received a 
placebo spot-on formulation to mimic the appear-
ance of the emodepside/praziquantel spot-on. In 
study no. 1 treatments were performed once on 
SD 0. Cats in study no. 2 were treated twice with a 
two-week interval (SD 0 and 14).
Necropsy
Necropsy was performed on several consecutive 
days starting on SD 26 in study no. 1 and SD 33 in 
study no. 2. The lungs, heart and trachea were 
removed. The lung tissue was cut into pieces of 
approximately 1 cm3 and checked for lungworms 
by dissecting piece by piece under a stereo micro-
scope. Lungworms were identified to species and 
counted. In study no. 2 the examination method 
for worms was modified to take the complicated 
worm count procedure into account and to avoid 
false negative results. As A. abstrusus is embedded 
very deeply in the lung parenchyma, it had to be 
considered that viable worms could be destroyed 
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and cut into pieces during isolation from the lung 
tissue. Additionally, worms might die during the 
examination due to the fact that the method is very 
time-consuming. Therefore each lungworm or part 
of a worm present was carefully examined under a 
stereo microscope and checked for viability, general 
appearance and structure of the integument. All 
worms which were obviously dead before necropsy 
started (i.e. lytic or necrotic worms with distinct 
changes of the integument) were counted as dead 
worms. For worm fragments the number of heads 
and tails present was determined. If the number 
of heads was greater than the number of tails, the 
heads were used to calculate the total number of 
worms and vice versa.
Efficacy determination and statistical analysis
The adequacy of infection was determined accord-
ing to VICH guidelines 7 and 20. In general, these 
guidelines consider a minimum of 6 animals in 
the control group with at least 5 worms each to 
be adequate. However, as the guidelines do not 
include specific recommendations for studies 
with A. abstrusus and lower infection rates were 
observed in a preliminary study (Schnyder et al. 
2014), an infection with at least one worm in each 
of 6 control animals was deemed to be adequate. 
Additionally, the lower limit of the 95  % confidence 
interval was required to be greater than 10  % of 
the geometric mean.
The efficacy was based on worm counts at necropsy 
and calculated according to VICH guideline 7 and 
the WAAVP guideline for evaluating the efficacy 
of anthelmintics for dogs and cats (Jacobs et al. 
1994) as follows:
% Effectiveness (reduction) = (N1 – N2)/N1 x 100
N1:  geometric mean (GM) of A. abstrusus counts in the 
control group
N2:  geometric mean (GM) of A. abstrusus counts in the 
treated group  
Due to the presence of worm count values of “0”, 
all counts were modified by adding 1 prior to log 
transformation and subtracting 1 from the anti-
log value. In study no. 1 efficacy calculations were 
based on total worm counts (live + dead). As the 
data were normally distributed, a parametric anal-
ysis of variance was used to test for a treatment 
group effect (emodepside/praziquantel vs. placebo). 
In study no. 2 calculations were performed on the 
live and total worm counts. The data were not nor-
mally distributed, therefore the non-parametric 
Wilcoxon rank sum test (two tailed, α = 0.05) was 
used to test for a treatment group effect.
At necropsy it became apparent that in both studies 
some control animals were infected with a second 
lungworm species identified as Troglostrongylus 
sp. Due to the fact that the L1 of this parasite is 
morphologically extremely similar to the L1 of 
A. abstrusus, the contamination was not detected 
at the faecal examinations. Therefore no valid 
data could be generated for the faecal larval reduc-
tion post treatment of A. abstrusus alone. Rather 
the faecal larval counts had to be considered as 
combined Aelurostrongylus and Troglostrongylus 
L1 counts. For informational purposes, descriptive 
statistics were calculated but no inferential analy-
sis was performed.
All analyses were performed using SAS software 
9.2 (SAS Institute, Cary, North Carolina, USA, 
2001).
Results
Faecal examinations
In study no. 1 pooled faecal samples were positive 
on 30 dpi. All individual samples were positive 
32 dpi, therefore the onset of patency could not be 
clearly determined. In study no. 2 one group sample 
was positive 30 dpi, and by 38 dpi lungworm lar-
vae were present in all individual faecal samples. 
Faecal larval counts in the control group of both 
studies continuously increased towards necropsy. 
Larval counts in emodepside/praziquantel-treated 
animals were reduced by ≥ 99.6 % at necropsy. 
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Results of the faecal L1 counts are presented in 
Fig. 1. As explained above, the data represent the 
combined faecal larval counts of A. abstrusus and 
Troglostrongylus sp.
Effi cacy evaluation
The requirements for an adequate infection were 
fulfilled in both studies. All control cats were 
infected. While 11 – 68 worms (geometric mean: 
28.8) were found at necropsy of control cats in study 
no. 1, the control group in study no. 2 harboured 
3 – 45 live worms (geometric mean: 8.9) and in total 
(live + dead) 5 – 95 worms (geometric mean: 17.6). 
Total worm counts in the treated group in study 
no. 1 were reduced by 73 % (p = 0.0070). In study 
no. 2 no live A. abstrusus were isolated from cats 
treated twice with emodepside/praziquantel. Thus, 
the efficacy based on live worm counts was 100 % 
(p = 0.0030). One cat harboured two dead worms. 
Based on total worm counts (live + dead) the effi-
cacy was 99.2 % (p = 0.0035). Results are summa-
rised in Table 2.
Fig. 1: Development of combined faecal larval counts A. abstrusus/Troglostrongylus sp. (geometric means).
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Table 2: Results of controlled studies on the efﬁ cacy of emodepside/praziquantel spot-on against adult Aelurostrongylus 
abstrusus nematodes.
Study 
no.
Group
Live worm counts Total worm counts (live + dead)
Range
Geometric 
mean
Reduction Range
Geometric 
mean
Reduction
1
placebo
Not evaluated*
11 – 68 28.8 –
emodepside/
praziquantel
1 – 40 7.8 73.0%
2
placebo 3 – 45 8.9 – 5 – 95 17.6 –
emodepside/
praziquantel
0 0.0 100% 0 – 2 0.1 99.2%
*differentiation between live and dead nematodes was not applicable.
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General health and safety evaluation
Apart from one cat in the treatment group, all cats 
in study no. 1 showed respiratory signs on at least 
one evaluation date. These were abnormal respira-
tory sounds, an abnormal breathing character and 
rate and coughing. Furthermore, signs probably 
related to lungworm were enlarged lymph nodes, 
lethargy, a rough coat and in rare cases cardio-
vascular signs. Due to pneumonia, one cat in the 
treatment group received concomitant treatment 
with meloxicam once on SD 22. The only abnormal 
clinical signs in study no. 2 were vomiting in three 
cats on a single occasion 10 or 11 dpi. Apart from 
that, all cats stayed clinically healthy throughout 
the study period. In both studies treatments were 
well tolerated. No adverse effects were observed.
Infection with Troglostrongylus sp.
Six control cats in study no. 1 harboured Troglos-
trongylus nematodes (range 2 – 23). In study no. 2 
four cats in the control group were infected. One 
cat harboured a single worm, in another cat three 
worms were present and two cats were infected 
with two Troglostrongylus sp. each. No Troglos-
trongylus worms were detected in any of the emod-
epside/praziquantel-treated cats.
Discussion
VICH Guidelines 7 and 20 require a reduction 
in worm burdens of at least 90 % in treated ani-
mals compared to a control group in order to claim 
efficacy of an anthelmintic substance. While this 
requirement was not met by a single treatment with 
emodepside/praziquantel spot-on, two treatments 
given at an interval of two weeks showed complete 
efficacy (100 %) based on live worm counts, and only 
two dead worms were isolated from a single cat in 
the treatment group. These results demonstrate 
that the combination of emodepside and praziquan-
tel is highly effective not only against a wide vari-
ety of gastrointestinal nematodes and cestodes, but 
also against a nematode that resides in the lung 
tissue such as A. abstrusus. Spot-on treatment is a 
convenient application method, especially for cats. 
Oral application can become highly challenging 
in these patients and is even more problematic in 
sick animals that refuse food or exhibit respira-
tory problems, as with clinical aelurostrongylosis. 
Thus, the topical formulation Profender® for cats 
has major advantages in the treatment of feline 
aelurostrongylosis compared to oral formulations 
of fenbendazole.
In both studies it became evident at necropsy that 
cats in the control group were infected with a sec-
ond lungworm species identified as Troglostron-
gylus sp. While adults of this species are clearly 
distinguishable from A. abstrusus, the L1 shed 
through faeces are extremely similar. In the past, 
nematodes of the genus Troglostrongylus have been 
considered to be associated only with wild felids 
(Di Cesare et al. 2015a) and prior to 2010, when the 
nematode was identified in cats from Ibiza, Spain 
(Jefferies et al. 2010), the parasitological communi-
ty was not aware of Troglostrongylus spp. infesta-
tions in domestic cats. Various authors speculated 
that especially T. brevior infections might have 
been confused with A. abstrusus in the past due to 
the extremely similar morphological features of the 
L1 and the fact that diagnosis is routinely based on 
faecal examinations (Brianti et al. 2012, Otranto 
et al. 2013, Traversa and Di Cesare 2013). In fact, 
this is what has happened in the studies presented 
here. The contamination with Troglostrongylus sp. 
was not identified until necropsy. Although meas-
ures were taken in the second study to avoid this 
contamination by checking the inoculation mate-
rial very carefully, some Troglostrongylus worms 
were again present in control animals.
There was a marked difference in clinical signs 
between the two studies. While in study no. 1 almost 
all cats showed signs of lung disease at least on one 
evaluation time point, cats in study no. 2 appeared 
to be healthy throughout the study. This difference 
was probably due to the lower challenge dose used 
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in study no. 2. Hamilton (1967) infected cats with 
doses ranging from 50 to 3200 L3. While minor 
clinical signs were present in kittens that received 
low infective doses, cats receiving 800 and more 
L3 displayed pronounced clinical signs of lung dis-
ease. These findings correlated with severe and 
widespread alterations of the lung tissue. The basis 
for study no. 1 was an experimental infection by 
Schnyder et al. (2014) that used infective doses of 
100 and 800 L3. As the differences in clinical and 
post mortem examinations between the infective 
doses were not as distinct as those described by 
Hamilton (1967), and an adequate infection rate 
was observed at the higher dose, it was decided 
to use 800 L3 in study no. 1. Due to the clinical 
signs observed in study no. 1, the infective dose was 
reduced in the second study. 
Although there is no proof that emodepside/
praziquantel-treated cats and the control groups 
were infected with Troglostrongylus sp. to a simi-
lar degree, it might be speculated that the treat-
ment was also effective against this species. No 
Troglostrongylus nematodes were recovered from 
treated animals, and from a statistical point of 
view it seems unlikely that the treated groups 
were not infected while contemporaneously the 
control animals showed a Troglostrongylus worm 
burden. Recently, Profender® spot-on was used to 
treat two cats with mixed infections with T. brevior 
and A. abstrusus in the one case and T. brevior and 
Capillaria aerophila co-infection in the other (Di 
Cesare et al. 2015b). After one or two administra-
tions (given two weeks apart) faeces were free of 
lungworm larvae/eggs and clinical signs resolved, 
providing further evidence of the anthelmintic effi-
cacy of emodepside against Troglostrongylus.
It can be concluded that two treatments with Pro-
fender® spot-on at an interval of two weeks are 
highly efficacious against adult A. abstrusus. The 
treatment regime is safe and the ease of application 
of the topical formulation is advantageous, espe-
cially in cases where oral dosing is problematic.
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